{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:04:09Z","timestamp":1775552649210,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multicentric Castleman disease (MCD), especially the HHV8-positive subtype, is a rare lymphoproliferative disorder that presents considerable diagnostic and therapeutic difficulties, particularly among HIV-positive patients. The co-occurrence of other infections, such as syphilis, may further complicate its clinical picture and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case description<\/jats:title>\n                    <jats:p>A 65-year-old man with well-controlled HIV presented with persistent fever, fatigue, and disseminated lymphadenopathy,. Through histopathological examination, molecular testing (including mNGS for HHV8), and PET-CT imaging, HHV8-positive MCD was diagnosed, along with latent syphilis. The patient was successfully treated with R-VP16 (rituximab and etoposide) for MCD and benzathine penicillin for syphilis, showing a positive clinical response. Throughout 36 months of continuous monitoring, the patient has maintained sustained complete remission with no evidence of disease recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the importance of considering HHV8-driven lymphoproliferative disorders in HIV patients with unexplained lymphadenopathy and systemic symptoms, particularly in HHV8-endemic regions. It also highlights the essential roles of advanced diagnostics and multidisciplinary management in such complex presentations. The favorable outcome demonstrates the effectiveness of timely and targeted treatment, though long-term follow-up remains necessary due to the potential for relapse or progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1779973","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:13:21Z","timestamp":1774930401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: HHV8-positive multicentric Castleman disease in an HIV-positive patient :diagnostic challenges arising from atypical histology and the role of metagenomic sequencing"],"prefix":"10.3389","volume":"16","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Chongqing Public Health Medical Center","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Chongqing Public Health Medical Center","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Chongqing Public Health Medical Center","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.annpat.2022.07.013","article-title":"La maladie de Castleman [Castleman disease","volume":"43","author":"Meignin","year":"2023","journal-title":"Ann Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1097\/TXD.0000000000001197","article-title":"Patients\u2019 Experiences with HIV-positive to HIV-positive organ transplantation","volume":"7","author":"Van Pilsum Rasmussen","year":"2021","journal-title":"Transplant Direct."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1515\/med-2020-0204","article-title":"CXCL13 concentration in latent syphilis patients with treatment failure","volume":"15","author":"Zhang","year":"2020","journal-title":"Open Med (Wars)."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000001321","article-title":"Outcomes from re-treatment and cerebrospinal fluid analyses in patients with syphilis who had serological nonresponse or lack of seroreversion after initial therapy","volume":"48","author":"Zhang","year":"2021","journal-title":"Sex Transm Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/2324709620967212","article-title":"Membranous glomerulonephritis as an uncommon presentation of secondary syphilis: A reminder on therapeutic decision-making in clinical practice","volume":"8","author":"Inayat","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3960\/jslrt.21036","article-title":"Historical and pathological overview of Castleman disease","volume":"62","author":"Nishimura","year":"2022","journal-title":"J Clin Exp Hematop."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153024","article-title":"Primary effusion lymphoma metachronous to multicentric Castleman disease in an immunocompetent patient","volume":"216","author":"Parente","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_2190_22","article-title":"Idiopathic multicentric Castleman disease","volume":"20","author":"Chaudhari","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2021.e01315","article-title":"Concurrent HIV viral blips during two episodes of multicentric Castleman disease in an adult on antiretroviral therapy: Implication for HIV persistence","volume":"26","author":"Darwish","year":"2021","journal-title":"IDCases."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.1034","article-title":"Interleukin-6 transcripts up-regulation in lymph nodes from unicentric and multicentric Castleman disease","volume":"5","author":"Lucioni","year":"2024","journal-title":"EJHaem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e28077","DOI":"10.1097\/MD.0000000000028077","article-title":"Human herpesvirus 8-associated multicentric Castleman disease in a patient with advanced HIV infection: A case report","volume":"100","author":"Guayboon","year":"2021","journal-title":"Med (Baltimore)."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073775","article-title":"Molecular features of HHV8 monoclonal microlymphoma associated with kaposi sarcoma and multicentric castleman disease in an HIV-negative patient","volume":"25","author":"Rogges","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e243195","DOI":"10.1136\/bcr-2021-243195","article-title":"Localised cervical lymphadenopathy: a rare presenting sign of syphilis","volume":"14","author":"Adriaansens","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.19.22334","article-title":"HIV lymphadenopathy: differential diagnosis and important imaging features","volume":"216","author":"Glushko","year":"2021","journal-title":"AJR Am J Roentgenol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.remnie.2021.10.005","article-title":"Contribution of 18F-FDG PET\/CT imaging in the diagnosis and management of HIV-positive patients","volume":"41","author":"Tatar","year":"2022","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010316","article-title":"Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease","volume":"7","author":"Rasmussen","year":"2023","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2025.102861","article-title":"A case of KSHV\/HHV8-positive large B-cell lymphoma in a background of HIV-negative KSHV\/HHV8-positive Multicentric Castleman disease","volume":"31","author":"Tsushima","year":"2025","journal-title":"J Infect Chemother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1024\/0040-5930\/a001111","article-title":"Nicht-neoplastische Erkrankungen des Lymphknotens: vom histologischen Muster zur Diagnose [Reactive Lymphadenopathies","volume":"76","author":"Vallejo","year":"2019","journal-title":"Ther Umsch."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2021.04.001","article-title":"Reactive lymphadenopathies","volume":"41","author":"Faraz","year":"2021","journal-title":"Clin Lab Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2024.01.003","article-title":"IgG4-related lymphadenopathy","volume":"41","author":"Cheuk","year":"2024","journal-title":"Semin Diagn Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03222-7","article-title":"Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease","volume":"115","author":"Kaga","year":"2022","journal-title":"Int J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003604","article-title":"Management of KSHV\/HHV8-positive multicentric castleman disease concurrent with other KSHV\/HHV8-positive disorders: an emergent challenge in PLWH","volume":"99","author":"Carbone","year":"2025","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1779973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T08:22:34Z","timestamp":1775550154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1779973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1779973"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1779973","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1779973"}}